A Phase 3 interventional study of Setmelanotide in Obesity Associated With Defects in Leptin-melanocortin Pathway, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 14th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 1 started in 2024.
This study's enrollment of 28 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 18th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromic, or acquired diseases of obesity upstream of the MC4R pathway.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily (QD) subcutaneous injection of setmelanotide
Drug: Setmelanotide
Open-label daily injections of setmelanotide
Also known as: RM-493, Imcivree
Safety and tolerability of setmelanotide assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Jun 2026, 20 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 20 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →